A new center being developed by Baylor College of Medicine and Rice University aims to develop ethically responsible and trustworthy AI for health care. Photo via Getty Images.

Baylor College of Medicine and Rice University have been awarded a $500,000 grant from the National Endowment for the Humanities (NEH) to create the Center for Humanities-based Health AI Innovation (CHHAIN).

The new center and three-year initiative aims to create ethically responsible and trustworthy AI for health care that uses history and patient narratives to shape the technology, according to a release. It represents a collaboration between the Center for Medical Ethics and Health Policy at Baylor and the Medical Humanities Research Institute at Rice. Ultimately, the researchers aim to establish a national model for integrating the humanities into the design and implementation of health AI.

Vasiliki Rahimzadeh, assistant professor at Baylor in the Center for Medical Ethics and Health Policy, and Kirsten Ostherr, director of the Medical Humanities Research Institute at Rice, will serve as co-directors of the new center, which will be housed within the Center for Medical Ethics.

The team will also engage in strategic collaborations with Kirstin Matthews, Rice’s Baker Institute for Public Policy and its fellow in science and technology policy, as well as Dr. Quianta Moore, executive director of the Meadows Mental Health Policy Institute. An interdisciplinary team of medical humanities and bioethics scholars from Baylor, Rice, and partners in the Houston area will complete the group.

“CHHAIN represents a bold new model for integrating the humanities into health innovation,” Ostherr said in a news release. “It will create a collaborative space where humanities scholars, patients, developers and clinicians can come together to explore the human dimensions of health AI—trust, narrative and lived experience. These are essential perspectives that are too often missing from technology development, and CHHAIN is designed to change that."

CHHAIN’s work will revolve around three key points:

  • Defining trustworthy AI through patient voices
  • Translating humanities insights into clinical AI settings
  • Public engagement and policy translation

“For AI to truly improve health outcomes, it must be designed with patient trust and wellbeing at its core,” Rahimzadeh said in the news release. “CHHAIN will provide a dedicated space to explore critical bioethics questions, such as how we ensure AI respects patient autonomy, addresses the needs of underserved communities and integrates meaningfully into clinical care. Our goal is to translate these insights into real-world health settings where AI is already shaping patient experiences."

CHHAIN's research mission was also developed thanks to pilot funding from the Margaret M. and Albert B. Alkek Department of Medicine at Baylor and a grant from Rice's Provost's TMC Collaborator Fund.

Texas A&M, the University of North Texas and the University of Texas at El Paso were also home to some of the 97 projects that received a portion of the $34.79 million in fundning from the NEH. See the full list here.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.

27 Houston companies make Fortune 500 for 2026, led by energy giants

Houston HQs

Editor's note: This article has been updated to correct the number of companies based in the Dallas-Fort Worth area.

Houston is a giant among U.S. hubs for corporate headquarters.

The 2026 Fortune 500 lists 27 companies based in the Houston area, with many energy companies claiming top spots. Houston ties with Chicago for the second-most Fortune 500 headquarters, preceded only by New York City (53). Dallas-Fort Worth is home to 24 Fortune 500 headquarters.

Texas leads the nation for Fortune 500 headquarters (57), with California in the No. 2 spot and New York at No. 3.

“Texas is the undisputed headquarters of headquarters,” Gov. Greg Abbott said in a news release. “The world’s leading businesses invest with confidence in Texas because of our welcoming business climate, predictable regulatory environment, and skilled and growing workforce. People and businesses are choosing Texas because Texas works.”

The 2026 Fortune 500 ranks the largest U.S. corporations based on revenue in fiscal year 2025.

Here’s a rundown of the 27 Fortune 500 companies based in the Houston area.

  • No. 9 ExxonMobil
  • No. 21 Chevron
  • No. 29 Phillips 66
  • No.55 Sysco
  • No. 75 ConocoPhillips
  • No. 89 Enterprise Products Partners
  • No. 103 Plains GP Holdings
  • No. 133 Hewlett Packard Enterprise
  • No. 149 NRG Energy
  • No. 157 Quanta Services
  • No. 164 Baker Hughes
  • No. 173 Occidental Petroleum
  • No. 179 Waste Management
  • No. 201 EOG Resources
  • No. 204 Group 1 Automotive
  • No. 207 Halliburton
  • No. 223 Cheniere Energy
  • No. 236 Corebridge Financial
  • No. 262 Targa Resources
  • No. 266 Kinder Morgan
  • No. 388 Westlake
  • No. 435 CenterPoint Energy
  • No. 438 APA
  • No. 440 Comfort Systems USA
  • No. 455 NOV
  • No. 488 KBR
  • No. 496 Coterra Energy. Oklahoma City, Oklahoma-based Devon Energy and Houston-based Coterra Energy merged in early May, with the combined company retaining the Devon Energy name and the Houston headquarters.

The Greater Houston Partnership notes the Houston area soon will welcome its 28th Fortune 500 company. Expand Energy (formerly Chesapeake Energy), appearing at No. 362 on the 2026 list, says it’s moving its headquarters from Oklahoma City to Spring this year.

As the natural gas producer prepares to relocate to Texas, it’s hunting for a new leader. Nick Dell’Osso stepped down as president and CEO earlier this year. Board Chairman Michael Wichterich is interim president and CEO.

Dell’Osso became president and CEO of Oklahoma City-based Gulfport Energy effective May 28.

---

This article first appeared on EnergyCapitalHTX.com.